Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:199077819 | Esophagus | ESCC | protein localization to cell periphery | 217/8552 | 333/18723 | 4.08e-13 | 1.88e-11 | 217 |
GO:000716320 | Esophagus | ESCC | establishment or maintenance of cell polarity | 143/8552 | 218/18723 | 2.05e-09 | 4.65e-08 | 143 |
GO:00469316 | Esophagus | ESCC | pore complex assembly | 16/8552 | 20/18723 | 1.85e-03 | 8.40e-03 | 16 |
GO:00350888 | Esophagus | ESCC | establishment or maintenance of apical/basal cell polarity | 32/8552 | 49/18723 | 4.39e-03 | 1.73e-02 | 32 |
GO:00612458 | Esophagus | ESCC | establishment or maintenance of bipolar cell polarity | 32/8552 | 49/18723 | 4.39e-03 | 1.73e-02 | 32 |
GO:00451978 | Esophagus | ESCC | establishment or maintenance of epithelial cell apical/basal polarity | 29/8552 | 44/18723 | 5.41e-03 | 2.02e-02 | 29 |
GO:199077811 | Liver | Cirrhotic | protein localization to cell periphery | 135/4634 | 333/18723 | 1.18e-10 | 6.21e-09 | 135 |
GO:000716312 | Liver | Cirrhotic | establishment or maintenance of cell polarity | 82/4634 | 218/18723 | 1.55e-05 | 2.11e-04 | 82 |
GO:0046931 | Liver | Cirrhotic | pore complex assembly | 12/4634 | 20/18723 | 8.43e-04 | 6.12e-03 | 12 |
GO:199077821 | Liver | HCC | protein localization to cell periphery | 200/7958 | 333/18723 | 6.07e-11 | 2.23e-09 | 200 |
GO:000716322 | Liver | HCC | establishment or maintenance of cell polarity | 133/7958 | 218/18723 | 2.48e-08 | 5.73e-07 | 133 |
GO:00469311 | Liver | HCC | pore complex assembly | 17/7958 | 20/18723 | 1.18e-04 | 9.87e-04 | 17 |
GO:199077816 | Oral cavity | OSCC | protein localization to cell periphery | 190/7305 | 333/18723 | 1.46e-11 | 5.13e-10 | 190 |
GO:000716318 | Oral cavity | OSCC | establishment or maintenance of cell polarity | 129/7305 | 218/18723 | 1.16e-09 | 2.86e-08 | 129 |
GO:00469315 | Oral cavity | OSCC | pore complex assembly | 15/7305 | 20/18723 | 1.19e-03 | 5.99e-03 | 15 |
GO:199077817 | Oral cavity | LP | protein localization to cell periphery | 133/4623 | 333/18723 | 4.42e-10 | 2.21e-08 | 133 |
GO:000716319 | Oral cavity | LP | establishment or maintenance of cell polarity | 79/4623 | 218/18723 | 8.84e-05 | 1.11e-03 | 79 |
GO:000716327 | Skin | cSCC | establishment or maintenance of cell polarity | 103/4864 | 218/18723 | 9.44e-12 | 4.85e-10 | 103 |
GO:199077824 | Skin | cSCC | protein localization to cell periphery | 134/4864 | 333/18723 | 7.09e-09 | 2.30e-07 | 134 |
GO:003508814 | Skin | cSCC | establishment or maintenance of apical/basal cell polarity | 26/4864 | 49/18723 | 4.78e-05 | 4.96e-04 | 26 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PDZD11 | insertion | Frame_Shift_Ins | novel | c.136_137insATTCTGTGCTCTTGTCTTACAGTTGGGATTTAACATCCGAGGAG | p.Arg46HisfsTer20 | p.R46Hfs*20 | Q5EBL8 | protein_coding | | | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
PDZD11 | insertion | In_Frame_Ins | novel | c.177_178insGATAAGCAGGCCAATCGT | p.Gly59_Phe60insAspLysGlnAlaAsnArg | p.G59_F60insDKQANR | Q5EBL8 | protein_coding | | | TCGA-BH-A0E2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
PDZD11 | SNV | Missense_Mutation | rs751113363 | c.367N>T | p.Arg123Cys | p.R123C | Q5EBL8 | protein_coding | tolerated(0.14) | possibly_damaging(0.465) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PDZD11 | SNV | Missense_Mutation | | c.188N>A | p.Arg63Gln | p.R63Q | Q5EBL8 | protein_coding | tolerated(0.11) | benign(0.003) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
PDZD11 | SNV | Missense_Mutation | novel | c.98N>G | p.His33Arg | p.H33R | Q5EBL8 | protein_coding | tolerated(0.05) | benign(0.047) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
PDZD11 | SNV | Missense_Mutation | rs751113363 | c.367N>T | p.Arg123Cys | p.R123C | Q5EBL8 | protein_coding | tolerated(0.14) | possibly_damaging(0.465) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PDZD11 | SNV | Missense_Mutation | novel | c.125N>T | p.Gln42Leu | p.Q42L | Q5EBL8 | protein_coding | tolerated(0.08) | benign(0.031) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PDZD11 | SNV | Missense_Mutation | novel | c.323G>A | p.Ser108Asn | p.S108N | Q5EBL8 | protein_coding | tolerated(0.12) | benign(0.13) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PDZD11 | SNV | Missense_Mutation | | c.111C>A | p.Asn37Lys | p.N37K | Q5EBL8 | protein_coding | deleterious(0.02) | probably_damaging(0.968) | TCGA-B5-A0JN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | SD |
PDZD11 | SNV | Missense_Mutation | novel | c.374G>A | p.Arg125His | p.R125H | Q5EBL8 | protein_coding | deleterious(0) | possibly_damaging(0.673) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |